FBRX - Conference and earnings call announcements

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. March 10-12, Dr. Wagner will be attending the Barclays 28th Annual Global Healthcare Conference hos

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, will be presenting at 3 upcoming healthcare conferences. Forte will be presenting at the Guggenheim 2nd Annual Healthcare Innovation Conference at the InterContinental Boston in Boston MA on Mon, Nov 10 at 3:30-3:55 PM ET. On Nov. 12 at 2:00-2:20 PM ET, Forte will present at the virtual TD Cowen Immunology and Inflammation Summit. Additionally on Dec 4 at 11:15-11:35 AM ET, Forte will be presenting at the 8th Annual Evercore Healthcare Conference in Coral Gables FL at the Loews Hotel. Source: Forte Biosciences, Inc. View sourc

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 3rd at 10:30 AM ET, Dr. Wagner will be presenting at the TD Cowen 45th Annual Healthcare Conference hosted at the Boston Marriott Copley Place in Boston, MA. About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing F

Exposes Misrepresentations and Distortions Included in Forte's Recent Presentation Encourages Stockholders to Vote for Independent Director Candidates Michael Hacke and Chris McIntyre on the WHITE Proxy Card Ahead of Forte's Upcoming Annual Meeting on September 19th Camac Partners, LLC ("Camac") and ATG Capital Management, LLC ("ATG") (together with the other participants in their solicitation, the "Concerned Stockholders," the "Group" or "we") collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (NASDAQ:FBRX) ("Forte" or the "Company"). Today, the Group and its independent director candidates – Michael Hacke and Chris McIntyre – responded to mi

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Chardan Annual Microbiome Medicines Summit on March 8th, 2021. Webcast Information Forte management will host a webcast on Monday March 8th, 2021 at 1.00 PM Eastern Time. Participants may access the webcast through the following link: https://wsw.com/webcast/chard7/fbrx/1860034 The webcast can also be accessed from the investor relations section of Forte’s website at https://www.fortebiorx.com. A replay of the webcast will also be available through Ma

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Cowen Annual Health Care Conference on March 1, 2021. Webcast Information Forte management will host a webcast on Monday March 1st, 2021 at 4.00 PM Eastern Time. Participants may access the webcast through the following link: https://wsw.com/webcast/cowen81/fbrx/1958682 The webcast can also be accessed from the investor relations section of Forte’s website at https://www.fortebiorx.com. A replay of the webcast will also be available through